tiftd.org
About the Institute | The Institute for Therapeutic Discovery
http://www.tiftd.org/about
Characterizing the success of this approach, MLI’s patent position led to a licensing agreement with Élan Corporation, plc, a multi-national pharmaceutical company. Under that agreement, Élan obtained rights to MLI’s intellectual property relating to the treatment of Alzheimer’s disease. Élan then embodied that technology in FDA-authorized clinical trials which are in progress. Early results have appeared in the scientific and popular presses. To accelerate this and related research into new frontiers, i...
ribsl.org
Rhode Island BioScience Leaders | Members
http://www.ribsl.org/members
Rhode Island BioScience Leaders. Development of a blood test to predict sudden cardiac death risk. Treatments for wound healing, rashes, skin infections. Bioactive and antimicrobial medical coatings. Biomedical textiles for device manufacturing. BioProcess testing, training and consultation. Drugs for Cystic Fibrosis. Neuromodulation and brain computer interfacing. Wound healing and delivery of regenerative factors. Immunoinformatics, vaccines, protein deimmunization. Materials Science Associates, LLC.
ncra.com
Press Releases and Publications from NCRA Norwich Clinical Research Associates Ltd.
http://www.ncra.com/press.php
Press Releases and Publications. Announces Successful Urinary Incontinence Clinical Trial. Release Date: November 6, 2012. Providence, RI- (BUSINESS WIRE)- Beech Tree Labs, Inc. announced today that it has completed a successful Phase 2a clinical evaluation of its novel therapeutic agent, UISH001, for treating urinary incontinence (UI). This FDA-authorized study was a multi-site, 67-patient, placebo-controlled trial. Beech Tree’s founder and CEO, Dr. John McMichael said, “The combined res...UI affects 20...
tiftd.org
Site References | The Institute for Therapeutic Discovery
http://www.tiftd.org/content/site-references
1 Oschman, James L. Energy Medicine: The Scientific Basis. Edinburgh, Scotland: Churchill Livingston, 2000, 43-48. 1 Clinical comparison of LDI-100, a preparation containing human chorionic gonadotropin and BCG, to single-agent vinblastine for treatment of canine mast cell tumors, Carolyn J. Henry, Sue Downing, Robert C. Rosenthal, Mary Kay Klein, Kari Meleo, J. Armando Villamil, Linda S. Fineman, Dudley L. McCaw, Mary Lynn Higginbotham, and John McMichael. American Journal of Veterinary Research. 73-77,...
tiftd.org
Molecular Therapies | The Institute for Therapeutic Discovery
http://www.tiftd.org/molecular
Heretofore, the Institute's research has centered on the discovery and early-stage evaluation of Resonant Molecular Signaling (RMS) therapeutic candidates. The continuing discovery and early-stage development of the various formulations comprising this platform is now the mission of the Institute's sister biopharmaceutical company, Beech Tree Labs, Inc. RMS is a novel platform that addresses a broad spectrum of disorders via a new therapeutic approach of intra- and extra-cellular signaling. Disharmony is...